Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events.
Determining incidence rates of potential adverse events before and after an immunisation programme is initiated, provides a useful framework for the evaluation of vaccine safety concerns. Human papillomavirus vaccination (HPV) of adolescent girls has recently been introduced in Denmark. Using a nationwide hospitalisation registry we estimated incidence rates of immune-mediated disorders before HPV vaccination in a cohort of 418,289 Danish girls aged 12-15 years. We further estimated the expected number of cases of immune-mediated disorders occurring in temporal relationship to a hypothetical HPV vaccination schedule purely by chance. Our results and analytical approach provides a framework for the evaluation of adverse event reports following immunisation of adolescent girls.
Callréus
Torbjörn
T
Division of Vaccine, Statens Serum Institut, Copenhagen, Denmark.
Svanström
Henrik
H
Nielsen
Nete Munk
NM
Poulsen
Sigrid
S
Valentiner-Branth
Palle
P
Hviid
Anders
A
D000293:Adolescent; D001327:Autoimmune Diseases / Q000453:epidemiology; D002648:Child; D003718:Denmark; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000453:epidemiology; D015994:Incidence; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology
D053918:Papillomavirus Vaccines